Immunotherapy Pioneer and Serial Biotech Entrepreneur Patrick Baeuerle to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on Biotechnology
Patrick Baeuerle, Ph.D., a pioneer of T cell engaging therapies and executive partner at life sciences venture firm MPM Capital, will give a keynote presentation about next-generation immuno-oncology therapies from Harpoon Therapeutics, Inc. at the upcoming European Congress on Biotechnology (ECB) on Tuesday, July 3 from 10:30 to 11:00 a.m. CEST in Geneva, Switzerland.
Dr. Baeuerle co-founded Harpoon Therapeutics in 2015 with a vision to build an innovative class of T cell engaging therapeutics optimized to achieve superior efficacy in penetrating solid tumors as an “off-the-shelf” T cell therapy. T cell engagers are unique in their ability to redirect lysis independently of T cell receptor (TCR) specificity and recognition of human leukocyte antigen (HLA) / peptide antigen – the loss of which being a frequent mechanism by which cancer cells escape T cell recognition.
His presentation, entitled “TriTAC™: A novel therapy to treat cancer,” will focus on compelling preclinical data from Harpoon’s TriTAC technology that underscores its potential to overcome the limitations and liabilities of existing T cell-engaging antibody therapies.
Supported by investments led by MPM and the UBS Oncology Impact Fund (OIF) managed by MPM, Harpoon Therapeutics anticipates launching two TriTAC programs in the clinic within the year. The company’s lead candidate, HPN424, targets prostate-specific membrane antigen (PSMA) and will be investigated for use in the treatment of patients with prostate cancer. Its second product candidate, HPN536, targets mesothelin and will be investigated for use in the treatment of patients with a variety of solid tumors.
Dr. Baeuerle, an immunologist by training, is known for his role in the development of the first bispecific T cell engager (BiTE) for hematologic malignancies, Blincyto® (blinatumomab), which was approved by the U.S. Food and Drug Administration (FDA) in less than 3 months in 2014 -- the fastest FDA approval for a cancer drug ever. In 2015, he joined MPM and since then has co-founded six companies with MPM and the UBS OIF in his continued pursuit of novel immunotherapies for cancer.
The ECB is the leading congress for academic and industrial biotechnologists in Europe and the flagship biennial event of the European Federation of Biotechnology. For complete details, please visit www.ecb2018.com.
About Harpoon Therapeutics
Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel antibody-based drug discovery platform called TriTAC™ (tri-specific T cell activating construct) to unleash the targeted cell-killing properties of a patient’s own immune system through T cell activation. This approach has been optimized to penetrate tissues and extend serum exposure, and has the potential to address a broad range of cancers, including solid tumors, and immunologic diseases. HPN424, a prostate-specific membrane antigen (PSMA)-targeting TriTAC™ biologic, is in development for the treatment of prostate cancer and is expected to enter a clinical trial in 2018. For more information, please visit www.harpoontx.com.
About MPM Capital
MPM Capital is a venture firm founding and investing in early-stage life sciences companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. MPM’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, neuroscience, metabolic disorders and regenerative medicine. With its experienced and dedicated investment team, executive partners and entrepreneurs, and its medical and scientific advisory board, MPM is powering novel medical breakthroughs that transform patients’ lives. MPM is currently investing from its BV2014 and BV2018 funds. It also invests from the UBS Oncology Impact Fund managed by MPM -- the first-of-its-kind, oncology-only social impact fund that donates a portion of its profits and royalties to cancer research and cancer care. For further information, please visit www.mpmcapital.com.
For MPM Capital
Liz Doherty, +1 617-425-9275
For MPM Capital/UBS Oncology Impact Fund
Kathy Vincent, +1 310-403-8951
For Harpoon Therapeutics
Kinkead Communications, Inc.
Susan Kinkead, +1 415-509-3610
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Alibaba Cloud and OBS Unveil Innovative Cloud Solutions for the Olympic Games19.9.2018 11:00 | Tiedote
Olympic Broadcasting Services (OBS) and Alibaba Cloud, the cloud computing arm of Alibaba Group, announced today the launch of OBS Cloud, an innovative broadcasting solution that operates entirely on the cloud, to help transform the media industry for the digital era. Set to be in place for Tokyo 2020, the OBS Cloud aims to offer all the necessary cloud components, in specialized configurations, that can support the extremely demanding content production and delivery workflows of the broadcasting of the Olympic Games. Tokyo 2020 will be a game-changer for broadcasters as it showcases new possibilities for the industry by presenting solutions on the cloud. The use of cloud technologies has been gradually adopted for content creation and distribution purposes in broadcasting, however the extremely demanding requirements for volume, speed and latency that are inherent in live sports broadcasting of major events have kept the use of the cloud at a very low level, despite its multiple advan
TRIPLE-1 Has Been Successful in the 50% Curtailment Compared to the Electricity Consumption of the Conventional Mining Machine19.9.2018 11:00 | Tiedote
TRIPLE-1, Inc. (Representative director: Takuya Yamaguchi) is publicizing the numerical performance evaluation of the mining machine, “KAMIKAZE”equipped with the 7nm ASIC chip this day, 19 th September 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005227/en/ Chip (Photo: Business Wire) -- The numerical performance evaluation of the mining machine, “KAMIKAZE” equipped with the 7nm ASIC chip will be publicized. This time, in the test of the performance evaluation of the mining machine, “KAMIKAZE” equipped with the 7nm ASIC chip, we have confirmed the result as follows. • “KAMIKAZE” Performance: Energy saving performance Hashrate : 14.5 TH / s ± 5% (* at the normal state) Power Consumption : 750 W ± 5% Power Efficiency : 0.052 W / GH ± 5% • “KAMIKAZE” Official Movie https://youtu.be/Fp_K4bV639Y The mining machine, ”KAMIKAZE” equipped with the world’s most advanced 7nm ASIC chip has the same Hashrate as the main min
Alibaba Cloud to Work with Kenyan Ministry to Protect Wildlife19.9.2018 10:42 | Tiedote
Alibaba Cloud, the cloud-computing arm of Alibaba Group, and the Ministry of Tourism and Wildlife of the Republic of Kenya today agreed to explore a strategic collaboration to deploy Alibaba Cloud’s technology to support the Kenya Wildlife Protection Project. The first project under the collaboration in discussion will take place at a designated area inside the Tsavo East and West National Parks, one of Kenya’s oldest and largest protected area with over 13,500 square kilometres. Leveraging Alibaba Cloud’s powerful computing, artificial intelligence (AI) and Internet of Things (IoT) capabilities; the project will work to protect the park’s endangered elephants, rhinoceroses and lions. “It is our great honour to support the Kenyan government and make a contribution to the country’s wildlife conservation efforts. The collaboration underscores the positive impact that technology, including cloud computing, AI and IoT, can have on the planet and on wildlife protection,” said Simon Hu, Seni
GE Transportation locomotives approved for operation by Indian Railways19.9.2018 09:00 | Tiedote
GE Transportation (NYSE:GE) announced today at InnoTrans 2018 that Indian Railways has confirmed its acceptance of GE’s 4,500-horsepower diesel-electric Evolution Series prototype locomotive. This critical milestone was achieved following the successful completion of rigorous testing on Indian Railways’ tracks following the locomotive handover in February 2018. “The acceptance of these locomotives is a testament to GE’s engineering depth and understanding of the customer requirements,” said Nalin Jain, President and CEO-APAC, GE Transportation. “This is a major step towards fulfilling our contract with Indian Railways. Together we will help modernize Indian Railways' fleet, significantly upgrade India's rail infrastructure and provide critical support for India's growing economy.” A standard practice, the acceptance of the 4500hp locomotives came after months of reviewing key design aspects, documentation and a thorough validation around various parameters in the U.S. and India. The lo
Toshiba Memory and Western Digital Celebrate the Opening of Fab 6 and Memory R&D Center at Yokkaichi, Japan19.9.2018 07:00 | Tiedote
Toshiba Memory Corporation and Western Digital Corporation (NASDAQ:WDC) today celebrated the opening of a new state-of-the-art semiconductor fabrication facility, Fab 6, and the Memory R&D Center, at Yokkaichi operations in Mie Prefecture, Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918006193/en/ Fab 6 and Memory R&D Center, Yokkaichi Operations (Photo: Business Wire) Toshiba Memory started construction of Fab 6, a dedicated 3D flash memory fabrication facility, in February 2017. Toshiba Memory and Western Digital have installed cutting-edge manufacturing equipment for key production processes including deposition and etching. Mass production of 96-layer 3D flash memory utilizing the new fab began earlier this month. Demand for 3D flash memory is growing for enterprise servers, data centers and smartphones, and is expected to continue to expand in the years ahead. Further investments to expand its production wil
Hillhouse Capital Closes US$10.6 Billion Fund IV19.9.2018 05:29 | Tiedote
Hillhouse Capital announced today the close of Hillhouse Fund IV, L.P. The fund was heavily oversubscribed, closing with aggregate commitments of US$10.6 billion. From partnering with visionary founders at company inception, to undertaking buyouts of iconic brands, the flexibility of Hillhouse's mandate enables it to be highly selective in choosing investments. Hillhouse Fund IV will pursue opportunities across the healthcare, consumer, technology and services sectors globally, with a focus on Asia. With the new fund, Hillhouse will continue to work closely with entrepreneurs and management teams in pursuit of sustainable, long-term growth. In its private equity investments, Fund IV will implement Hillhouse's strategy of leveraging its extensive operating capabilities and deep understanding of technology to create long-term value. Hillhouse aims to reignite growth through digital enablement of traditional businesses, as it has done in the retail space with its buyout of Belle Internati
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme